The prevalence of diabetes and other non-communicable diseases (NCDs) in India has significantly risen, according to a study by the Madras Diabetes Research Foundation and the Indian Council of Medical Research. As a result, personalised and Precision Medicine will become increasingly relevant in the country, as "customised approaches" are needed for diabetes and hypertension care. German Pharma Major Boehringer Ingelheim, which has developed a medicine portfolio focused on curing NCDs, including empagliflozin and linagliptin, aims to reduce the number of deaths caused by NCDs, which account for 7 out of 10 worldwide.

The post Precision Medicine Next Big Thing in India with Rising Diabetes, BP, Obesity, Says German Pharma Major appeared first on Balanced News Summary.